Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic gene-edited CD33-knockout hematopoietic stem and progenitor cells

A preparation of human allogeneic hematopoietic stem and progenitor cells (HSPCs) that are ex-vivo gene-edited to remove the cluster of differentiation 33 (CD33) antigen, that can potentially be used to improve hematopoietic recovery after hematopoietic cell transplantation (HCT) and CD33-targeting therapy. Upon administration, allogeneic gene-edited CD33-knockout HSPCs increase and restore the number of HSPCs, which may prevent or decrease infection and other complications of HCT and chemotherapy-induced neutropenia (CIN). The removal of CD33 protects the agent from the cytotoxic effects of CD33-targeted agents administered after HCT.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic CD33KO-HSPC
allogeneic gene-edited CD33-depleted HSCs
allogeneic gene-edited CD33-knockout HSPCs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search